Nyrada Inc.

NYR

AU0000070195

Pharmaceuticals

Delayed Australian S.E. Other stock markets 02:10:49 2024-06-19 am EDT			5-day change	1st Jan Change
0.066 ^AUD	+11.86%		-2.94%	+200.00%

Apr. 30	Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	MT
Apr. 18	Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024

Nyrada Inc. Announces Appointment of Christopher Cox as Director

January 15, 2020 at 05:13 pm EST

Nyrada Inc. announced the appointment of Christopher Cox as Director. Date of appointment is 7 November 2019.

Latest news about Nyrada Inc.

Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury	Apr. 29	MT
Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024	Apr. 17
Transcript : Nyrada Inc. - Special Call	Apr. 10
Nyrada Begins Animal Testing on NYR-BI03 Brain Injury Program	Apr. 09	MT
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate	Mar. 27	MT
Nyrada Raises AU$1.8 Million via Placement	Mar. 05	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 20	CI
Nyrada Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2023; Shares Surge 30%	Dec. 08	MT
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-27	CI
Australian Shares Flat as June Unemployment Rate Remains at 3.5%	23-07-20	MT
Nyrada Halves Director Fees; Shares Jump 37%	23-07-20	MT
Nyrada Opts to Advance NYR-BI03 Brain Injury Drug Candidate	23-06-12	MT
Nyrada Completes Preclinical Studies on Cholesterol Lowering Medication	23-05-25	MT
Nyrada Completes Preclinical Dose Formulation for Cholesterol Lowering Medication	23-04-11	MT
Nyrada Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Nyrada Extends R&D Deal for Brain Injury Drug Candidate	23-01-18	MT
Nyrada Inc. Announces Collaboration with Walter Reed and UNSW Extended to 2025	23-01-17	CI
Nyrada Advances Preclinical Studies for Brain Injury Drug Candidate	23-01-10	MT
Nyrada Inc. Provides Update on the Progress of Its Brain Injury Program	23-01-10	CI
Nyrada Receives $804,600 R&D Tax Refund; Shares fall 11%	22-11-17	MT
Nyrada Inc. Announces Efficacy Study Published in Journal of Lipid Research	22-10-09	CI
Nyrada Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Nyrada Inc. Announces Board Changes	22-08-01	CI
Nyrada Validates Effectivity of Inhibitor Drug to Block Early Atherosclerosis; Shares Fall 6%	22-07-19	MT
Nyrada Delays Phase 1 Cholesterol Trial Due to Lockdown in China; Shares Fall 7%	22-06-28	MT

Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Companyâs two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NYRADA INC.	+200.00%	7.14M
ELI LILLY AND COMPANY	+52.93%	803B
NOVO NORDISK A/S	+40.98%	629B
JOHNSON & JOHNSON	-7.08%	351B
MERCK & CO., INC.	+17.40%	324B
ABBVIE INC.	+10.58%	303B
ASTRAZENECA PLC	+16.42%	244B
ROCHE HOLDING AG	+2.17%	226B
NOVARTIS AG	+10.66%	215B
AMGEN INC.	+6.24%	164B